![Magnus Nylén](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Magnus Nylén
Directeur/Membre du Conseil chez
SELECTIMMUNE PHARMA AB (PUBL)
Profil
Magnus Nylén is currently Director at Hamlet BioPharma AB starting in 2025.
Mr. Nylén is also Director at SelectImmune Pharma AB since 2022.
Additionally, Mr. Nylén has been Owner at Partner Fondkommission AB since 2013.
Mr. Nylén completed undergraduate education at Boston University.
Postes actifs de Magnus Nylén
| Sociétés | Poste | Début |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Directeur/Membre du Conseil | 23/11/2022 |
| HAMLET PHARMA AB (PUBL) | Directeur/Membre du Conseil | 11/03/2025 |
Partner Fondkommission AB
 Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Corporate Officer/Principal | 01/01/2013 |
Formation de Magnus Nylén
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
6
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Partner Fondkommission AB
Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Finance |
Hamlet BioPharma AB
 Hamlet BioPharma AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products specifically for cancer patients | Health Technology |
SelectImmune Pharma AB
 SelectImmune Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops and manufactures immune enhancers to complement antibiotics | Health Technology |
